Medical Coverage Policy | Pegloticase (Krystexxa)



EFFECTIVE DATE: 02|11|2011 **POLICY LAST UPDATED:** 11|21|2017

OVERVIEW

This policy documents the coverage criteria for Pegloticase (KrystexxaTM). Pegloticase is a PEGylated uric acid-specific enzyme indicated for the treatment of chronic gout in adult patients' refractory to conventional therapy.

MEDICAL CRITERIA

BlueCHiP for Medicare and Commercial Products

Krystexxa (pegloticase) will be approved when ALL of the following are met:

1. ONE of the following:

A. There is documentation that the patient is currently being treated with the requested agent for an FDA approved indication

OR

B. The prescriber states the patient is using the requested agent for an FDA approved indication AND is at risk if therapy is changed

OR

- C. ALL of the following:
 - i. The patient has a baseline serum uric acid level of at least 8 mg/dL

AND

- ii. ONE of the following:
 - 1. The patient has symptomatic gout with at least 3 gout flares in the previous 18 months

OR

2. The patient has at least 1 gout tophus or gouty arthritis

AND

iii. ONE of the following:

1. The patient is currently (within the last 30 days) receiving prophylaxis for gout flares with NSAIDS or colchicine or both

OR

2. The patient had a documented intolerance, FDA labeled contraindication or hypersensitivity to both NSAIDs and colchicine

AND

iv. ONE of the following:

1. The patient has had an insufficient response (defined as uric acid levels > 6 mg/dL) to at least 3 months of therapy with both allopurinol and febuxostat at maximum tolerated doses

OR

2. The patient has a documented intolerance, FDA labeled contraindication or hypersensitivity to both allopurinol and febuxostat

AND

- 2. The patient does not have any FDA labeled contraindications to therapy with the requested agent **AND**
- 3. The dose is within the FDA labeled dose

Length of Approval: 6 months

The requested agent will also be approved when the following are met:

- 1. The patient does not have any FDA labeled contraindications to therapy with the requested agent **AND**
- 2. The use of the target agent is for an indication that is supported by compendia. (NCCN CompendiumTM[level of evidence 1, 2A], AHFS, DrugDex [FDA approved Class I or Class IIa]), or the prescriber has submitted additional documentation (the use is supported by clinical research in 2 or more peer reviewed medical journals) supporting the requested therapeutic use (approval by the Clinical Review Pharmacist required).
 - AND
- 3. The requested dose is within FDA labeling or dose is supported by compendia. (NCCN CompendiumTM[level of evidence 1, 2A], AHFS, DrugDex [FDA approved Class I or Class IIa]), or the prescriber has submitted additional documentation (the dose is supported by clinical research in 2 or more peer reviewed medical journals) supporting the requested therapeutic dose (approval by the Clinical Review Pharmacist required)

Length of Approval: 6 months

Renewal Evaluation

Krystexxa (pegloticase) will be renewed when ALL the following are met:

- 1. The patient has been previously approved for therapy through the BCBSRI Medical Drug Review process
 - AND
- The patient does not have 2 consecutive uric acid levels > 6 mg/dL while on therapy AND
- 3. The patient does not have any FDA labeled contraindications to therapy with the requested agent **AND**
- 4. The dose is within the FDA labeled dose

Length of Approval: 12 months

The requested agent will also be approved when the following are met:

- 1. The patient has been previously approved for therapy through the BCBSRI Medical Drug Review process
 - AND
- 2. The patient does not have any FDA labeled contraindications to therapy with the requested agent **AND**
- The use of the target agent is for an indication that is supported by compendia. (NCCN CompendiumTM[level of evidence 1, 2A], AHFS, DrugDex [FDA approved Class I or Class IIa]), or the prescriber has submitted additional documentation (the use is supported by clinical research in 2 or more peer reviewed medical journals) supporting the requested therapeutic use (approval by the Clinical Review Pharmacist required). AND
- 4. The requested dose is within FDA labeling or dose is supported by compendia. (NCCN Compendium[™][level of evidence 1, 2A], AHFS, DrugDex [FDA approved Class I or Class IIa]), or the prescriber has submitted additional documentation (the dose is supported by clinical research in 2 or more peer reviewed medical journals) supporting the requested therapeutic dose (approval by the Clinical Review Pharmacist required)

Length of Approval: 12 months

PRIOR AUTHORIZATION

Prior authorization is required for BlueCHiP for Medicare and recommended for Commercial products.

POLICY STATEMENT

BlueCHiP for Medicare and Commercial Products

Pegloticase (Krystexxa) is medically necessary when the criteria listed above have been met.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable physician administered drug benefits/coverage.

Specialty Pharmacy

For contracts with specialty drug coverage, please refer to the member agreement for benefits and preauthorization guidelines.

BACKGROUND

Pegloticase (KrystexxaTM) has been indicated for the treatment of chronic gout in adult patients' refractory to conventional therapy. Pegloticase (KrystexxaTM) is a PEGylated uric acid-specific enzyme that reduces serum uric acid levels by catalyzing the oxidation of uric acid to allantoin.

Pegloticase is a PEGylated uric acid-specific enzyme that consists of recombinant modified mammalian urate oxidase produced by a genetically modified strain of *Escherichia coli* (Krystexxa prescribing information, 2010). It is approved for the treatment of chronic gout in adult patients' refractory to conventional therapy.

Krystexxa is not recommended for the treatment of asymptomatic hyperuricemia.

The following requirements should be documented in the medical records:

- Uric acid levels will be monitored prior to each infusion; and
- For continuation of therapy, two consecutive uric acid levels must NOT be above 6 mg/dL; and
- Patients at high risk for glucose 6-phosphate dehydrogenase (G6PD) deficiency (e.g., African or Mediterranean ancestry) must be screened before initiation of therapy <u>and</u> must have negative results; and
- Krystexxa will be administered in a healthcare setting with access to management of severe anaphylaxis and infusion reactions; and
- Patient will be premedicated with antihistamines and corticosteroids prior to each infusion.

CODING

BlueCHiP for Medicare and Commercial Products

The following HCPCS code is medically necessary when the medical criteria are met: **J2507** Injection, Pegloticase, 1 mg

RELATED POLICIES

None

PUBLISHED

Provider Update, January 2018 Provider Update, December 2016 Provider Update, December 2015 Provider Update, September 2014 Provider Update, May 2013 Provider Update, April 2012

REFERENCES

1. Krystexxa prescribing information. Crealta. May 2016.

2. Khanna, D., et al. 2012 American College of Rheumatology Guideline Management of Gout part 1. Arthritis Care & Research: Vol 64, No 10, October 2012, pp 1431-1446.

3. Rothschild BM. Gout and Psuedogout. Medscape.

4. Sivera F, Andres M, Carmona L et al. Recommendations for the Diagnosis and Management of Gout. *Ann Rheum Dis* 2014; 73(2):328-335.

5. Qaseem Amir, et al. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. Doi: 10.7326/M16-0570. November 2016.

----- CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.